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259Abstracts
CAP. METHODS: In 2 independent, randomized,
double-blind, multicenter clinical studies, 1023 adult out-
patients (Study 1, n = 448; Study 2, n = 575) with CAP
received TEL 800mg once daily for 10 (Study 1) or 5 or
7 days (Study 2), or CLA 500mg twice daily for 10 days
(comparator regimen, both studies). Clinical and eco-
nomic outcomes were followed for four weeks. The
primary statistical hypothesis was equivalence of clinical
efﬁcacy (per-protocol populations). Economic outcomes
in the intent to treat populations were assessed by 
non-protocol-driven CAP-related resource use. Unit costs
were assigned as follows (Study 1/2): additional antibi-
otics/medications using 1999/2000 Redbook average
wholesale prices; physician visits/tests/procedures using
Medicare’s Resource Based Relative Value Scale; and 
hospitalizations using 1999/2000 American Hospital
Association national average daily rates for short-term
hospitalization. Data from the two studies were pooled
and analyzed. RESULTS: The clinical efﬁcacy of TEL 
and CLA was equivalent (88.8% [428/482] vs 90.1%
[272/302], respectively). Patients treated with TEL had
fewer CAP-related hospitalizations vs CLA patients
(13/612 [2.6%] vs 15/411 [3.6%], respectively). The
length of stay in hospital was shorter for TEL vs CLA
patients (16.8 vs 33.8 hospital days per 100 patients,
respectively). Concomitant antibiotics were required by
135/612 (22.1%) TEL vs 110/411 (26.8%) CLA patients.
The average per-patient cost of additional resource use
for TEL ($309) was considerably less than that for CLA
($622), with per-patient savings of $313 for TEL. Greater
savings were observed for the subset of patients aged 65
years: average per-patient cost of additional resource use
for TEL of $305 vs $896 for CLA, with per-patient
savings of $591 for TEL. CONCLUSIONS: TEL is an
effective therapy for outpatients with CAP and is associ-
ated with lower direct healthcare costs than CLA.
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OBJECTIVES: Treatment of CAP is becoming more 
difﬁcult because of changes in the antibiotic resistance
patterns of pathogens causing CAP, particularly S. 
pneumoniae. This purpose of this study is to assess the
economic impact of changes in hospitalization and mor-
tality rates in CAP due to antimicrobial resistance.
METHODS: The costs of CAP were determined from 
an administrative claims database from 1996–1998 for
an employed population and their dependents under the
age of 65 (N > 100,000). The economic impact of antibi-
otic resistance on CAP costs was simulated under differ-
ent scenarios. The simulations were based on the
assumptions that antibiotic resistance might increase the
mortality rate, the hospitalization rate, or both the mor-
tality and hospitalization rates in CAP. RESULTS: We
identiﬁed 7,249 episodes of CAP. The hospitalization rate
was 19.6% and the mortality rate among inpatient CAP
episodes was 9.1%. The average cost of treatment for an
inpatient episode of CAP (including all inpatient and out-
patient medical care) was $10,227. Costs for inpatients
who died during hospitalization ($15,822) were higher
than for episodes in which patients were discharged alive
($9,595). Increasing the mortality rate by an additional
5% (to 14.1%) led to a 3% increase in the total costs 
of treatment. Increasing the hospitalization rate from the
observed rate of 20% to 25% increased total costs by
28%. CONCLUSIONS: Simulations indicate that, if
antibiotic resistant organisms increase outpatient treat-
ment failures and resultant hospitalization rates for CAP,
there would be a substantial economic impact. The total
annual economic impact of treating CAP in the U.S. is
estimated to be $12.1 billion. If resistance leads to higher
mortality rates and hospitalization rates, the total annual
economic impact of treating CAP in the U.S. could rise
by 23% to $14.9 billion.
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OBJECTIVES: To evaluate the cost-effectiveness of line-
zolid, compared to teicoplanin, for serious gram-positive
infections from a randomized trial, which showed that
linezolid had superior efﬁcacy especially in bacteremia
(ICAAC 2001; L-1481), a trend toward shorter LOS
(ECCMID 2002; O140) and lower mean adjusted total
cost of treatment (SCCM 2003; 200). METHODS: Hos-
pitalized patients from 6 European (n = 227) and 7 South
American (n = 203) countries with serious gram-positive
infections including pneumonia, complicated skin/soft
tissue infections, or bacteremia were treated with line-
zolid (intravenous followed by optional oral) or
teicoplanin (intravenous followed by optional intra-
muscular) for up to 4 weeks, followed by up to 3 weeks
of observation. Investigator-assessed end-of-treatment
success/failure was used to determine effectiveness,
missing/indeterminate evaluations were either scored as
failures or imputed using logistic regressions. Resource
use during the 49-day study period was collected and
